Press coverage about Roka Bioscience (NASDAQ:ROKA) has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Roka Bioscience earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.3678548288476 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Roka Bioscience (NASDAQ:ROKA) traded down $0.07 during mid-day trading on Tuesday, reaching $1.10. The company’s stock had a trading volume of 626,602 shares, compared to its average volume of 2,080,000. Roka Bioscience has a 12-month low of $0.66 and a 12-month high of $6.75.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.watchlistnews.com/roka-bioscience-roka-earning-somewhat-positive-media-coverage-report-shows/1686500.html.

In other Roka Bioscience news, major shareholder Orbimed Advisors Llc sold 75,276 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $1.52, for a total value of $114,419.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 894,570 shares of company stock valued at $741,435 in the last quarter. Corporate insiders own 29.20% of the company’s stock.

Roka Bioscience Company Profile

Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.

Insider Buying and Selling by Quarter for Roka Bioscience (NASDAQ:ROKA)

Receive News & Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.